Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT02392611
Detect V / CHEVENDO (Chemo vs. Endo)
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Prof. Wolfgang Janni
- Target Recruit Count
- 271
- Registration Number
- NCT02344472
- Locations
- 🇩🇪
University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT02291913
- Locations
- 🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States
🇺🇸Hope Cancer Center, Terre Haute, Indiana, United States
🇺🇸Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 283
- Registration Number
- NCT02258451
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 85
- Registration Number
- NCT02248571
- Locations
- 🇩🇪
iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany
ER Reactivation Therapy for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 19
- Registration Number
- NCT02188745
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Baystate Medical Center, Springfield, Massachusetts, United States
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 164
- Registration Number
- NCT02123823
- Locations
- 🇰🇷
National Cancer Center, Goyang, Korea, Republic of
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇦🇹LKH-Univ. Hospital Graz, Graz, Austria
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
- Conditions
- Interventions
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 608
- Registration Number
- NCT02115282
- Locations
- 🇺🇸
Eisenhower Medical Center, Rancho Mirage, California, United States
🇺🇸Mercy Cancer Center - Sacramento, Sacramento, California, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT02077933
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
🇺🇸Memorial Sloan Kettering Cancer Center SC - BYL719Z2102, New York, New York, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 92
- Registration Number
- NCT02069093
- Locations
- 🇺🇸
Regional Cancer Care Associates Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States
🇺🇸Hematology Oncology Associates of Northern New Jersey PA DeptofHem-OncofNorthern NJ (2), Morristown, New Jersey, United States
🇺🇸Highlands Oncology Group Highlands Oncology Group (22), Fayetteville, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.